GUARDANT HEALTH has partnered with SWOG on a study to use cell-free DNA testing to identify mechanisms of resistance and future treatment options in non-small cell lung cancer. SWOG chose Guardant360 as the blood test for a tumor genomic profiling study of approximately 600 lung cancer patients. The study will test patients at the time...
A group of melanoma experts, joined by three advocacy groups focused on melanoma, has engaged FDA in a public discussion of the challenges of developing new drugs in the refractory setting and the role crossover can play in such trials.
